Experience of etanercept treatment in juvenile ankylosing spondyloarthritis
https://doi.org/10.15690/vsp.v12i2.632
Abstract
A history case of severe juvenile ankylosing spondyloarthritis, characterized by rapid development of asymmetric polyarticular syndrome, sacroiliitis, patient’s incapacity and low quality of his and his family life, is discussed in this article. The activity of pathological process was managed to be suppressed due to successful usage of soluble tumor necrosis factor α receptor — etanercept. As a result of treatment the recurrence of articular syndrome was arrested, the function in almost all of the involved joints was recovered, laboratory markers of inflammatory activity decreased. Non-active stage of the disease was established in 12 weeks of etanercept treatment, remission — in 9 months.
About the Authors
A. N. Fetisova
Scientific Centre of Children Health, RAMS, Moscow,
Russian Federation
Russian Federation
E. I. Alexeeva
Scientific Centre of Children Health, RAMS, Moscow;
I.M. Sechenov First Moscow State Medical University,
Russian Federation
Contacts: Alekseyeva Yekaterina Iosifovna, PhD, MD, professor, Head of Rheumatological Department, National Center of Children’s Health, Russian Academy of Medical Sciences, Dean of Pediatric Faculty, I.M. Sechenov First Moscow State Medical University Address: 119991, Moscow, Lomonosovskiy Prospect, 2, bldg. 1, Tel.: (499) 134-02-97, e-mail: alekatya@yandex.ru
Russian Federation
Contacts: Alekseyeva Yekaterina Iosifovna, PhD, MD, professor, Head of Rheumatological Department, National Center of Children’s Health, Russian Academy of Medical Sciences, Dean of Pediatric Faculty, I.M. Sechenov First Moscow State Medical University Address: 119991, Moscow, Lomonosovskiy Prospect, 2, bldg. 1, Tel.: (499) 134-02-97, e-mail: alekatya@yandex.ru
T. M. Bzarova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
T. V. Sleptsova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
References
1. Hofer M. Spondylarthropathies in children — are they different from those in adults? Best Pract. Res. Clin. Rheumatol. 2006; 20: 315–328.
2. Evans D. M., Spencer C. C., Pointon J. J., Su Z. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat. Genet. 2011; 43 (8): 761–767.
3. Nikishina I. P. Juvenile ankylosing spondyloarthritis. Practical guideline on children’s diseases. Vol. III. Common edition of V. F. Kokolina, A. G. Rumyantsev. Moscow: Medpraktika-M. 2004. Pp. 620–649.
4. Tse S. M., Burgos-Vargas R., Laxer R. M. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum. 2005; 52 (7): 2103–2108.
5. Feldtkeller E., Lind-Albrecht G., Rudwaleit M. Core set of recommendations for patients with ankylosing spondylitis concerning behaviour and environmental adaptations. Rheumatol. Int. 2013. [Epub ahead of print]
6. Sulpice M., Deslandre C. J., Quartier P. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropa thies. Joint Bone Spine. 2009; 76 (1): 24–27. Doi: 10.1016/j.jbspin.2008.03.008. Epub: 2008 Dec 12.
7. Gerloni V., Pontikaki I., Gattinara M., Desiati F., Lupi E., Lurati A., Salmaso A., Fantini F. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum. 2005; 52 (2): 548–553.
8. Nasonov Ye. L. Pharmacotherapy of rheumatoid arthritis in era of genetically-engineered biological drugs. Therapeutic archive. 2007; 5: 5–8.
9. Kuek A., Hazleman B. L., Ostor A. J. K. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad. Med. J. 2007; 83: 251–269.
10. Takeuchi T. Indications for and use of biologics in early rheumatoid arthritis based on the evidence. Nippon Rinsho. 2009; 67 (5): 1043–1049.
11. Zhang Z., Bridges S. L., Jr. Pathogenesis of rheumatoid arthritis: role of B lymphocytes. Rheum. Dis. Clin. North Am. 2001; 27: 335–353.
12. Minden K., Niewerth M., Listing J. et al. Long-term outcome in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2002; 46: 2392–2401.
13. Foster H. E., Marshall N., Myers A., Dunklet P., Griffiths I. D. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003; 48: 767–775.
14. El-Gabalawy H. S., Lipsky P. E. Why do we not have a cure for rheumatoid arthritis? Arthritis Res. 2004; 4 (Suppl. 2): 297–301.
15. Horneff G., Burgos-Vargas R. Juvenile idiopathic arthritis. Subgroup characteristics and comparisons between rheumatoid arthritis-like subgroups and ankylosing spondylitis-like subgroups. Clin. Exp. Rheumatol. 2009; 27 (4, Suppl. 55): 131–138.
16. Lovell D. J., Reiff A., Ilowite N. T., Wallace C. A. et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58 (5): 1496–1504.
17. Robinson R. F., Nahata M. C., Hayes J. R., Rennebohm R. et al. Quality-of-life measurements in juvenile rheumatoid arthritis patients treated with Etanercept. Clin. Drug Investig. 2003; 23 (8): 511–518.
18. Kimura Y., Pinho P., Walco G., Higgins G., Hummell D., Szer I. et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 2005; 32 (5): 935–942.
19. Russo R. A., Katsicas M. M., Zelazko M. Etanercept in systemic juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2002; 20 (5): 723–726.
20. Lovell D. J., Reiff A., Ilowite N. T., Wallace C. A. et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58 (5): 1496–1504.
21. Otten M. H., Prince F. H., Armbrust W., ten Cate R., Hoppenreijs E. P., Twilt M., Koopman-Keemink Y., Gorter S. L., Dolman K. M., Swart J. F., van den Berg J. M., Wulffraat N. M., van Rossum M. A., van Suijlekom-Smit L. W. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011; 306 (21): 2340–2347. Doi: 10.1001/jama.2011.1671. Epub: 2011 Nov 6.
22. Cai Y., Liu X., Zhang W., Xu J., Cao L. Clinical trial of etanercept tapering in juvenile idiopathic arthritis during remission. Rheumatol. Int. 2013. [Epub ahead of print].
23. Ungar W. J., Costa V., Burnett H. F., Feldman B. M., Laxer R. M. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: A systematic review. Semin. Arthritis Rheum. 2013. pii: S0049-0172 (12)00263-6. Doi: 10.1016/ j.semarthrit.2012.10.006. [Epub ahead of print].
24. Moreland L. W., Schiff M. H., Baumgarthner S. W. et al. Etanercept therapy in rheumatoid arthritis. Ann. Int. Med. 1999; 130: 478–486.
25. Horneff G., De Bock F., Foeldvari I., Girschick H. J. et al. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann. Rheum. Dis. 2008; 0: ard.2007.087593v1.
26. Prince F. H., Twilt M., ten Cate R., van Rossum M. A. et al. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann. Rheum. Dis. 2008; 0: ard.2007.087411v1.
27. Nielsen S., Ruperto N., Gerloni V., Simonini G. et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2008; 26 (4): 688–692.
28. Lovell D. J., Reiff A., Ilowite N. T., Wallace C. A. et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58 (5): 1496–1504.
29. Nielsen S., Ruperto N., Gerloni V., Simonini G. et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2008; 26 (4): 688–692.
30. Quartier P., Taupin P., Bourdeaut F., Lemelle I., Pillet P., Bost M. et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003; 48 (4): 1093–1101.
31. Kozlova A. L., Alekseyeva Ye. I., Valiyeva S. I. Efficacy of infliximab in patients with juvenile ankylosing spondylo arthritis. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 8 (2): 20–26.
32. Alekseyeva Ye. I., Kozlova A. L., Valiyeva S. I. New opportunities of a treatment of juvenile ankylosing spondyloarthritis. Voprosi sovremennoi pediatrii — Current Pediatrics. 2010; 9 (2): 23.
33. Bzarova T. M., Alekseyeva Ye. I., Fetisova A. N., Tsurikova N. A., Valiyeva S. I., Denisova R. V., Mitenko Ye. V., Sleptsova T. V., Isayeva K. B., Chistyakova Ye. G., Tabuylatov N. I., Ryazanov M. V., Anikin A. V., Zelikovich Ye. I., Kurilenkov G. V., Semikina Ye. L. A place of soluble TNFа receptors in treatment of juvenile idiopathic arthritis. Voprosi sovremennoi pediatrii — Current Pediatrics. 2012; 11 (4): 29–37.
34. Fetisova A. N., Alekseyeva Ye. I., Bzarova T. M., Taybulatov N. I., Starikova A. V., Anikin A. V., Bekdzhanyan G. A. An experience of treatment with etanercept in early juvenile ankylosing spondyloarthritis. Voprosi sovremennoi pediatrii — Current Pediatrics. 2012; 11 (2): 169–175.
Review
For citations:
Fetisova A.N., Alexeeva E.I., Bzarova T.M., Sleptsova T.V. Experience of etanercept treatment in juvenile ankylosing spondyloarthritis. Current Pediatrics. 2013;12(2):131-138. (In Russ.) https://doi.org/10.15690/vsp.v12i2.632
Views:
685
Email this article 
